| Autor: |
Zedan AH; 1 Urological Research Center, Department of Urology, Vejle Hospital, Vejle, Denmark.; 2 Oncological Department, Vejle Hospital, Vejle, Denmark.; 3 Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark., Hansen TF; 2 Oncological Department, Vejle Hospital, Vejle, Denmark.; 3 Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark., Assenholt J; 4 Department of Biochemistry and Immunology, Vejle Hospital, Vejle, Denmark., Pleckaitis M; 5 Department of Clinical Pathology, Vejle Hospital, Vejle, Denmark., Madsen JS; 3 Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.; 4 Department of Biochemistry and Immunology, Vejle Hospital, Vejle, Denmark., Osther PJS; 1 Urological Research Center, Department of Urology, Vejle Hospital, Vejle, Denmark.; 3 Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark. |
| Abstrakt: |
Prostate cancer is the most common cancer among men in the western world. Clinical practice is continuously challenged by the pitfalls of the available diagnostic tools. microRNAs may represent promising biomarkers in many types of human cancers, including prostate cancer. The aim of this study was to investigate microRNA expression in tumour tissue and matched plasma in a cohort of patients with primary metastatic prostate cancer. The relative expression of 12 microRNAs was assessed in diagnostic needle biopsies from the prostate and matched plasma samples in two prospective cohorts (screening cohorts) comprising 21 patients with metastatic prostate cancer and 25 control patients. An independent validation cohort of plasma samples was collected prospectively from 149 newly diagnosed patients with local/locally advanced prostate cancer. Analyses were performed using real-time polymerase chain reaction. miRNA-93 showed a significant negative correlation between expression in tumour tissue and plasma in patients with metastatic prostate cancer. Furthermore, the plasma level of miRNA-93 significantly decreased after treatment in patients with local/locally advanced prostate cancer compared to baseline plasma level. The expression of six microRNAs (let-7b, miRNA-34a, -125b, -143, -145 and -221) was downregulated, and three microRNAs (miRNA-21, -25 and miRNA-93) were upregulated in tumour tissue compared to benign prostate tissue. In plasma, six microRNAs were upregulated (miRNA-21, -125b, -126, -141, -143 and -375), while let-7b was downregulated in patients with metastatic prostate cancer compared to the control cohort. In the metastatic prostate cancer cohort, the expression of four microRNAs (miRNA-125b, -126, -143 and -221), and miRNA-141 in tissue was associated with Gleason score and prostate-specific antigen, respectively. The expression of miRNA-93 in tumour tissue was correlated with matched plasma levels and showed a significant decrease in plasma level after intervention in local prostate cancer. Differential expression between tumour and benign prostate was detected for several microRNAs in both tissue and plasma. |
